| The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer (NCT00097344) | Intarcia Therapeutics | 2004-12-01 |
| Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin (NCT00932165) | Pfizer | 2004-12-01 |
| Diagnostics and Therapy of Disease-Related Quality of Life of Patients With Breast Cancer (NCT00145743) | Tumor Center Regensburg | 2004-11-01 |
| Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy (NCT00146536) | Dana-Farber Cancer Institute | 2004-11-01 |
| Early Detection of Breast Cancer Using Tomosynthesis Imaging (NCT00637598) | Duke University | 2004-11-01 |
| Proton MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response. (NCT00184288) | Norwegian University of Science and Technology | 2004-11-01 |
| Administration of Autologous Dendritic Cells (DCs) Infected With an Adenovirus Expressing Her-2 (NCT00197522) | Hamilton Health Sciences Corporation | 2004-10-01 |
| Exercise in Women at Risk for Breast Cancer (NCT00092950) | National Cancer Institute (NCI) | 2004-09-23 |
| To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent (NCT00620100) | Sanofi | 2004-09-01 |
| A Study of E7389 in Advanced/Metastatic Breast Cancer Patients (NCT00097721) | Eisai Inc. | 2004-09-01 |
| Evaluating Patient Information Prescriptions (NCT00355381) | Johns Hopkins University | 2004-09-01 |
| Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer (NCT00324259) | Washington University School of Medicine | 2004-08-01 |
| Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma (NCT00403988) | American University of Beirut Medical Center | 2004-06-01 |
| Study of Fluorodeoxyglucose (FluGlucoScan) in Patients With Breast Cancer: Correlation With Histologic Findings of Sentinel Node Biopsies and Axillary Dissection (NCT00123799) | AHS Cancer Control Alberta | 2004-06-01 |
| Genetic and Protein Profiling in Normal and Cancerous Breast Tissue (NCT00083733) | National Cancer Institute (NCI) | 2004-05-27 |
| Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer (NCT00083993) | Wyeth is now a wholly owned subsidiary of Pfizer | 2004-05-01 |
| Rehabilitation of Cancer Survivors in Denmark: The Effect of a Psychosocial Rehabilitation Course (NCT01086683) | Danish Cancer Society | 2004-05-01 |
| Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer (NCT00079625) | National Cancer Institute (NCI) | 2004-03-05 |
| A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies. (NCT00078000) | Pfizer | 2004-03-01 |
| MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma. (NCT00147550) | Pfizer | 2004-02-01 |
| BAY43-9006 - Phase II in Advanced Breast Cancer (NCT00101400) | Bayer | 2004-02-01 |
| Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer (NCT01695226) | Maastricht University Medical Center | 2004-02-01 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients (NCT00080197) | Eisai Inc. | 2004-02-01 |
| AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer (NCT00076024) | Pfizer | 2004-02-01 |
| The Use of Silver Leaf Dressing in the Prevention of Radiotherapy Induced Skin Reactions (NCT00207324) | British Columbia Cancer Agency | 2004-01-01 |
| Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer (NCT00073528) | Novartis Pharmaceuticals | 2003-12-09 |
| A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer (NCT00191672) | Eli Lilly and Company | 2003-12-01 |
| Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis (NCT00646555) | National Cancer Institute (NCI) | 2003-11-20 |
| Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine (NCT00072852) | Pfizer | 2003-11-01 |
| Establishment of a Tumor Bank for Blood Samples (NCT01763125) | Medical University of Vienna | 2003-11-01 |
| Study Evaluating HKI-272 in Tumors (NCT00146172) | Puma Biotechnology, Inc. | 2003-11-01 |
| Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer (NCT00073073) | Georgetown University | 2003-11-01 |
| GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer (NCT00617968) | Sanofi | 2003-10-01 |
| Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2 (NCT00071383) | National Institute of Neurological Disorders and Stroke (NINDS) | 2003-10-01 |
| Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study (NCT00229697) | AstraZeneca | 2003-10-01 |
| Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor-Associated Vasculature in Patients With Metastatic Breast Cancer (NCT00071357) | National Institute of Neurological Disorders and Stroke (NINDS) | 2003-10-01 |
| A Clinical Trial to Reduce Skin Burn Induced by Breast Radiotherapy Using Intensity Modulated Radiation Therapy (IMRT) (NCT00187343) | Sunnybrook Health Sciences Centre | 2003-09-01 |
| Establishment of a Tumor Bank for Tissue Samples (NCT01789229) | Medical University of Vienna | 2003-09-01 |
| Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer (NCT00210028) | Institut Claudius Regaud | 2003-08-01 |
| Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy (NCT00063570) | Eli Lilly and Company | 2003-07-01 |
| Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy (NCT00067314) | Pfizer | 2003-06-01 |
| Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer (NCT00525642) | Fudan University | 2003-06-01 |
| Studying Normal Breast Tissue and Cancer Risk (NCT00341692) | National Cancer Institute (NCI) | 2003-04-07 |
| Effects of Aerobic Exercise Versus Weight Training in Breast Cancer Survivors During Chemotherapy (NCT00115713) | University of Alberta | 2003-04-01 |
| Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer (NCT00052169) | NSABP Foundation Inc | 2003-01-01 |
| Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Mammography, Including Cost Comparisons (NCT00649337) | SonoCine, Inc. | 2003-01-01 |
| Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED) (NCT00092196) | Merck Sharp & Dohme LLC | 2002-12-01 |
| A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer (NCT00050427) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2002-12-01 |
| Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms (NCT00062751) | Wyeth is now a wholly owned subsidiary of Pfizer | 2002-12-01 |
| A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer (NCT00246597) | Ortho Biotech Products, L.P. | 2002-12-01 |
| A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer (NCT00051051) | Pfizer | 2002-12-01 |
| Implementation of Quality of Life Diagnostics and Therapy (NCT00141635) | Tumor Center Regensburg | 2002-12-01 |
| Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer (NCT00048893) | National Cancer Institute (NCI) | 2002-11-01 |
| Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients (NCT00128778) | Spanish Breast Cancer Research Group | 2002-10-28 |
| An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071) (NCT00092183) | Merck Sharp & Dohme LLC | 2002-10-10 |
| Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer (NCT00242203) | Washington University School of Medicine | 2002-10-01 |
| Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer (NCT02254005) | Boehringer Ingelheim | 2002-10-01 |
| Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents (NCT00191438) | Eli Lilly and Company | 2002-10-01 |
| PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) (NCT00043368) | Pfizer | 2002-09-01 |
| Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy (NCT00050011) | Novartis Pharmaceuticals | 2002-09-01 |
| The Use of Pentoxifylline and Vitamin E in the Treatment of Chronic Breast Pain (NCT00188669) | University Health Network, Toronto | 2002-07-01 |
| Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial (NCT00522262) | AHS Cancer Control Alberta | 2002-06-01 |
| Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer (NCT00044291) | Intarcia Therapeutics | 2002-06-01 |
| Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women (NCT00040014) | Pfizer | 2002-06-01 |
| This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer (NCT00034918) | Genzyme, a Sanofi Company | 2002-05-01 |
| Phase 2 Study of TLK286 in Metastatic Breast Cancer (NCT00035841) | Telik | 2002-04-01 |
| Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients (NCT00044525) | Bayer | 2002-04-01 |
| A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease (NCT00191373) | Eli Lilly and Company | 2002-03-01 |
| A Phase III Trial For Patients With Metastatic Breast Cancer (NCT00191152) | Eli Lilly and Company | 2002-02-01 |
| Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant (NCT00919399) | Institut Claudius Regaud | 2002-01-01 |
| A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer (NCT00034827) | Pfizer | 2002-01-01 |
| Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen (NCT00038103) | Pfizer | 2002-01-01 |
| Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer (NCT00279448) | Pfizer | 2002-01-01 |
| EPO906 Therapy in Patients With Advanced Breast Cancer (NCT00035126) | Novartis Pharmaceuticals | 2002-01-01 |
| Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer (NCT00048633) | QLT Inc. | 2001-11-01 |
| Investigating the Impact of Tailored Reports on Anxiety Amongst Cancer Patients and Their Confidants (NCT00127465) | University of Plymouth | 2001-11-01 |
| Acupuncture for Shortness of Breath in Cancer Patients (NCT00067691) | National Center for Complementary and Integrative Health (NCCIH) | 2001-11-01 |
| Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients (NCT00174343) | Pfizer | 2001-11-01 |
| Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel (NCT00039780) | BioNumerik Pharmaceuticals, Inc. | 2001-09-01 |
| Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane (NCT00036270) | Pfizer | 2001-08-01 |
| Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver (NCT00041808) | FeRx | 2001-07-01 |
| RCT of a Group Intervention for Women With a Family History of Breast Cancer (NCT00150917) | University Health Network, Toronto | 2001-07-01 |
| ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer (NCT00046514) | Celgene Corporation | 2001-06-01 |
| Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer (NCT00046527) | Celgene Corporation | 2001-06-01 |
| Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer (NCT00021255) | Sanofi | 2001-04-01 |
| Massage Therapy for Cancer-Related Fatigue (NCT00039793) | National Center for Complementary and Integrative Health (NCCIH) | 2001-03-01 |
| Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients (NCT00037609) | M.D. Anderson Cancer Center | 2001-01-01 |
| Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70 (NCT00027131) | UConn Health | 2000-12-01 |
| A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy (NCT00211133) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2000-06-01 |
| SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer (NCT00272740) | AstraZeneca | 2000-03-01 |
| Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer (NCT00041652) | Gilead Sciences | 2000-02-01 |
| Perioperative Chemotherapy After Primary Chemotherapy for Locally Advanced Breast Cancer (NCT00301548) | European Institute of Oncology | 2000-02-01 |
| Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue (NCT00184210) | Norwegian University of Science and Technology | 2000-01-01 |
| Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics (NCT00341458) | National Cancer Institute (NCI) | 1999-09-01 |
| Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment (NCT00121992) | Spanish Breast Cancer Research Group | 1999-07-01 |
| A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab (NCT00001805) | National Cancer Institute (NCI) | 1999-03-01 |
| BIG 02/98 Docetaxel - Breast Cancer (NCT00174655) | Sanofi | 1998-06-01 |
| Raloxifene Use for The Heart (NCT00190593) | Eli Lilly and Company | 1998-06-01 |
| Prospective Study of Health in Runners and Walkers (NCT00005494) | National Heart, Lung, and Blood Institute (NHLBI) | 1998-06-01 |
| German Preoperative Adriamycin Docetaxel Study (NCT00543829) | GBG Forschungs GmbH | 1998-04-01 |